SAR245409 + rituximab

SAR245409 + rituximab is an experimental combination therapy investigated in relapsed or refractory indolent B-cell non-Hodgkin lymphoma (iNHL), mantle cell lymphoma (MCL), and chronic lymphocytic leukemia (CLL). SAR245409 (also known as TCD12012) is an oral, small molecule dual inhibitor of the phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) pathways, which are key regulators of cell growth, proliferation, and survival. Rituximab is a chimeric monoclonal antibody that targets CD20 on B lymphocytes, leading to cell lysis primarily through antibody-dependent cellular cytotoxicity, complement activation, and direct apoptosis. The combination aims to exploit the complementary mechanisms of a targeted signal transduction inhibitor (SAR245409) and B-cell depletion (rituximab) to enhance antitumor activity in B-cell malignancies[1][3].